DCM
SUPN icon

Delpha Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Delpha Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-207
Closed -$8K – 1079
2017
Q4 		$8K Buy
+207
New +$8.18K 0.01% 1150

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $3.89B AUM 16.15% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
RCAMU
Rothschild & Co Asset Management US Stamford, Connecticut $6.58B AUM 4.5% 1-Year Est. Return

Delpha Capital Management's SUPN Position: Q1 2018 in Review

Delpha Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q1 2018, closing a stake of 207 shares — an estimated $8K sold.

Delpha Capital Management first reported a position in SUPN in Q4 2017 and held it in 1 quarter. The position peaked at $8K in Q4 2017. 312 funds tracked by Wall St. Rank hold SUPN as of Q1 2018.

  • Delpha Capital Management reported no remaining Supernus Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 207 Supernus Pharmaceuticals shares in Q1 2018, an estimated $8K.
  • Delpha Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Supernus Pharmaceuticals position peaked at $8K in Q4 2017.
  • 312 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.